A randomised, placebo-controlled, Phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma

I-MAT will determine if a six-month treatment regime of Avelumab is well-tolerated and can eliminate residual microscopic cancer cells, thus reducing the risk of the cancer reoccurring and improving the overall outcomes for patients with early-stage Merkel cell carcinoma.

Primary Sponsor

Melanoma and Skin Cancer Trials Limited (MASC Trials)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Accrual Target

132

Final Accrual

122

Expected Date of Accrual

June 2024

Trial Chairperson

Dr Wen Xu, Princess Alexandra Hospital, QLD, Australia

Trial Contact

imat@masc.org.au

Related Post

Geoff Zipper - aka Swamp - on the Kokoda Trail
26 June, 2025

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

LATEST NEWS: 26 June 2025 He may be 76

24 June, 2025

TROG 2024 Annual Research Report highlights a year of achievements

LATEST NEWS: 24 JUNE 2025 The latest annual report